Table 2 In silico analisys of miR-21 predicted target genes in HCC and Fatty Liver disease (mirwalk2.0).

From: Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model

HCC

HCC and FATTY LIVER

FATTY LIVER

AKT2, BASP1, BCL2, CCL20, CCNG1, CCR1, CCR7, CD47, CDC25A, CDK6, CLOCK, EDIL3, EGFR, ERBB2, FANCC, FAS, FASLG, FGF18, FUBP1, IL12A, IL1B, JAG1, KLK10, LIFR, MATN2, MEF2A, MEF2C, MMP2, MMP9, MSH2, MTAP, MUC1, MYC, NCOA3, NFKB1, PARP1, PDCD4, PER3, PIK3C2A, PIK3R1, PTEN, PTK2, RB1, RDH11, RPL36A, RTN4, SKP2, SLC2A1, SP1, SPDYA, SPRY2, STAT3, TGFBI, TGFBR3, TIAM1, TP53BP2, TP63, WNT5A

E2F1, ICAM1, PPARA, TGFB1, VEGFA

CLOCK, EIF2S1, LUM, TNFRSF11B

Back to article page